Impax Laboratories (IPXL +0.1%) bucks a weak tape on positive comments out of Canaccord this...
Thursday, August 23, 2012, 2:54 PM ETImpax Laboratories (IPXL +0.1%) bucks a weak tape on positive comments out of Canaccord this morning. The firm says there are a number of positive catalysts down the road that will likely drive the stock higher, including: remediation of the FDA's warning letter; an Adderall XR settlement with Shire (SHPGY); and the pending FDA decision on it's Parkinson's disease drug Rytary which is due October 21.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles